Just wrapped up calls with one of the $INTZ analysts as well as Investor Relations -- I'm still very bullish on $INTZ.
$INTZ is a $450M company with 2022 revenue estimates of $55-65M which means 150% top line growth with 70% gross margins.
Intro video:
$INTZ has done DoD work for 30+ years ($8-10 million per year) but now they are taking all of that data & expertise to launch an enterprise product called Shield.
Congrats to $TMDX for receiving the approval vote from the FDA panel hearing on OCS Heart 🚀 prnewswire.com/news-releases/…
Even though yesterday was a big day for $TMDX shareholders the bigger catalyst is still coming when $TMDX gets approval for DCD (donation after circulatory death) who.int/servicedeliver…
We also have OCS Liver approval on the horizon.
Because of all these catalysts Jason Mills from Canaccord Genuity raised his price target last month to $79 (more than 100% upside from current prices) streetinsider.com/Analyst+Commen…
I'm not sure who is selling $TMDX today but thank you for the gift because I'm buying your shares.
I'll keep betting on $TMDX because I've seen the competition and it sucks.
$TMDX OCS Heart vs. The Ice Cooler
$TMDX has their FDA panel hearing tomorrow; although these events are unpredictable I believe the data is overwhelming and $TMDX will eventually receive approval for DCD and DBD.
I would not be surprised if funds were selling their shares and/or shorting $TMDX to put pressure on the stock price so they could load up on call options. Don't get shaken out of your highest conviction companies.